Related Experiment Videos
[Diabetes and arterial hypertension]
1Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi Via Giustiniani, 2 35126 Padova.
Insights
Type II diabetes and hypertension often coexist with obesity, significantly increasing cardiovascular risks. Aggressive treatment, including ACE-inhibitors, is crucial for managing blood pressure and improving patient outcomes.
Area of Science:
- Endocrinology and Cardiovascular Medicine
- Metabolic Syndrome Research
Context:
- Type II diabetes and hypertension are prevalent comorbidities in adults, particularly in developed nations.
- Obesity exacerbates the cardiovascular risks associated with diabetes and hypertension, creating a significant public health challenge.
- The co-occurrence of these conditions elevates the risk of cardiovascular complications far beyond that of isolated hypertension.
Purpose:
- To highlight the increased cardiovascular risk in patients with coexisting Type II diabetes, hypertension, and obesity.
- To discuss the contributing factors to this elevated risk, including hyperglycemia, metabolic syndrome (Syndrome X), and hyperinsulinemia.
- To emphasize the necessity of aggressive non-pharmacological and pharmacological therapeutic strategies.
Summary:
- The combination of Type II diabetes, hypertension, and obesity leads to a substantially higher risk of cardiovascular complications.
- Factors such as hyperglycemia, metabolic syndrome (hyperlipemia, hyperuricemia, thrombophilia, altered Na(+)-H+ membrane exchanges), and hyperinsulinemia contribute to atherosclerosis and clinical events.
- Effective management necessitates aggressive therapeutic approaches, often involving multiple antihypertensive medications.
- Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers are recommended, especially for hypertensive patients with diabetes and proteinuria.
Impact:
- Aggressive blood pressure control is universally recognized as the most effective strategy for improving prognosis in this high-risk population.
- Understanding the interplay between diabetes, hypertension, obesity, and metabolic factors is key to developing targeted interventions.
- The findings underscore the importance of comprehensive management strategies to mitigate cardiovascular events in patients with these comorbidities.
Abstract:
Type II diabetes and hypertension are two pathologies which are frequently associated in adults, especially in developed countries. All the more so when patients are also obese: obesity is today, and will be in the next future, a true epidemic in these countries. These three pathologies imply a risk for cardiovascular complications much higher than that due to an isolated arterial hypertension. This increased risk is probably due to many factors: hyperglycemia, a dismetabolic syndrome (hyperlipemia, hyperuricemia, thrombophilia, altered Na(+)-H+ membrane exchanges = syndrome X) and hyperinsulinemia which favor atherosclerosis and clinical events. Consequently non-pharmacological and aggressive pharmacological therapy is necessary. Even if the trials done in the last years are questionable and not totally convincing, all researchers agree that lowering blood pressure to normality is the best way to improve prognosis of these patients. Usually for this purpose we need a therapy with more than one drug. Among the antihypertensive drugs, ACE-inhibitors (and perhaps also angiotensin receptor blockers) are preferred, especially in those hypertensives with diabetes who have also microalbuminuria or a frank proteinuria.